Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG)
Elżbieta Iskierka‐Jazdzewska(Copernicus Memorial Hospital), Krzysztof Jamroziak(Instytut Hematologii i Transfuzjologi), Paulina Wieszczy(Postgraduate School of Molecular Medicine), Janusz Hałka(Wojskowy Instytut Medycyny Lotniczej), Magdalena Piotrowska(The University of Texas System), Małgorzata Wojciechowska(Medical University of Warsaw), Marek Dudziński(Rzeszów University), Marek Hus(Medical University of Lublin), Elżbieta Mądro(Instytut Hematologii i Transfuzjologi), Jadwiga Hołojda(Witelon State University of Applied Sciences in Legnica), Agnieszka Szeremet(Wroclaw Medical University), Joanna Drozd‐Sokołowska(Medical University of Warsaw), Weronika Piszczek, Sławomira Kyrcz‐Krzemień(Medical University of Silesia), Paweł Steckiewicz(Holy Cross University), Marek Osowiecki(The Maria Sklodowska-Curie National Research Institute of Oncology), Beata Kumiega(Lublin Oncology Center), Wanda Knopińska‐Posłuszny, Tadeusz Robak(Medical University of Lodz), Jan Maciej Zaucha(Gdańsk Medical University), Krzysztof Giannopoulos(Medical University of Lublin), Krzysztof Warzocha(Instytut Hematologii i Transfuzjologi)
Cited by 39
Related Papers
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630